[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Halozyme: A Decade of Platform Revenue Finally Gets Its First Real Stress Test

Halozyme Therapeutics (HALO) reports first-quarter 2026 earnings on May 11, 2026, with investors focused on whether the biotech can rebound from a shocking Q4 miss that sent shares tumbling. The company's drug delivery platform technology, which enables subcutaneous administration of biologics through its ENHANZE platform, has driven strong royalty growth—but last quarter's $-0.35 loss versus a $2.07 consensus raised questions about one-time charges and the sustainability of the growth trajectory. With shares trading at $64.12 and analysts projecting a return to profitability, this report will test whether the Q4 stumble was an anomaly or a sign of deeper challenges.

Fundamentals

See More
  • Market Capitalization, $K 7,596,553
  • Shares Outstanding, K 118,474
  • Annual Sales, $ 1,397 M
  • Annual Income, $ 316,890 K
  • EBIT $ 594 M
  • EBITDA $ 687 M
  • 60-Month Beta 0.89
  • Price/Sales 5.53
  • Price/Cash Flow 13.66
  • Price/Book 157.05

Options Overview Details

View History
  • Implied Volatility 49.64% (+7.87%)
  • Historical Volatility 29.06%
  • IV Percentile 98%
  • IV Rank 86.86%
  • IV High 52.70% on 08/05/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 5) 3.13 (4.88%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 470
  • Volume Avg (30-Day) 531
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 14,884
  • Open Int (30-Day) 13,180
  • Expected Range 60.99 to 67.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.46
  • Number of Estimates 4
  • High Estimate $1.55
  • Low Estimate $1.37
  • Prior Year $1.03
  • Growth Rate Est. (year over year) +41.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.38 +2.79%
on 05/01/26
70.32 -8.82%
on 04/23/26
-1.31 (-2.00%)
since 04/08/26
3-Month
61.33 +4.56%
on 03/27/26
82.22 -22.01%
on 02/09/26
-17.11 (-21.06%)
since 02/06/26
52-Week
47.50 +34.99%
on 05/14/25
82.22 -22.01%
on 02/09/26
-3.61 (-5.33%)
since 05/08/25

Most Recent Stories

More News
Halozyme: A Decade of Platform Revenue Finally Gets Its First Real Stress Test

Barchart Research What to Expect from HALO Earnings HALO Generated May 8, 2026 Current Price $64.12 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme: A Decade of Platform Revenue...

HALO : 64.12 (-1.64%)
Halozyme Therapeutics Earnings: What To Look For From HALO

Halozyme Therapeutics Earnings: What To Look For From HALO

HALO : 64.12 (-1.64%)
Halozyme: A Decade of Platform Revenue Finally Gets Its First Real Stress Test

Barchart Research What to Expect from HALO Earnings HALO Generated May 8, 2026 Current Price $64.12 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme: A Decade of Platform Revenue...

HALO : 64.12 (-1.64%)
Halozyme: A Decade of Platform Revenue Finally Gets Its First Real Stress Test

Barchart Research What to Expect from HALO Earnings HALO Generated May 8, 2026 Current Price $64.12 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme: A Decade of Platform Revenue...

HALO : 64.12 (-1.64%)
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Marks first ENHANZE ® agreement to include ADC targets

HALO : 64.12 (-1.64%)
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hyperconâ„¢ Technology

Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target

HALO : 64.12 (-1.64%)
Halozyme's Royalty Engine Hums Along, But Partner Pipeline Momentum Remains the Real Question

Barchart Research What to Expect from HALO Earnings HALO Generated May 4, 2026 Current Price $64.57 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme's Royalty Engine Hums Along,...

HALO : 64.12 (-1.64%)
Halozyme to Report First Quarter 2026 Financial and Operating Results

SAN DIEGO , April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday,...

HALO : 64.12 (-1.64%)
Halozyme Appoints Darren Snellgrove as Chief Financial Officer

SAN DIEGO , April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Officer,...

HALO : 64.12 (-1.64%)
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm

FVRR : 11.45 (-2.55%)
CXW : 20.33 (-6.83%)
HALO : 64.12 (-1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 67.04
2nd Resistance Point 66.41
1st Resistance Point 65.26
Last Price 64.12
1st Support Level 63.49
2nd Support Level 62.86
3rd Support Level 61.71

See More

52-Week High 82.22
Fibonacci 61.8% 68.96
Fibonacci 50% 64.86
Last Price 64.12
Fibonacci 38.2% 60.76
52-Week Low 47.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.